NCT07826676
Use of Bone Marrow Stem Cells (MesenCell) for the Treatment of Patients With Chronic Graft-versus-host Disease
StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Start date pushed from Oct 2026 to Feb 2027
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Number of Participants With Treatment-Related Adverse Events
Timeframe: 30 days after the last MesenCell infusion
Secondary (8)
Overall Treatment Response Rate
Change in Overall Response
Change in Organ-Specific Response Scores
All-cause mortality
Failure-Free Survival
Show 3 moreShow less
Reduction in Corticosteroid Therapy
Discontinuation of Immunosuppressive Therapy
Time to Best Overall Response
Arms and interventions
MesenCellExperimental
Patient will receive 1 to 3 intravenous infusions of 2 × 10⁶/kg of Mesenchymal stem cells (MSCs) at 7 day intervals
Biologicals: Mesenchymal Stem Cell Infusion
Sites
4 sites in 1 country